Precision Medicine and Health Consortium (PMHC)
The Precision Medicine and Health Consortium capitalizes on the expertise within the scientific community, health systems, payor industry and others to make novel discoveries and therapeutic advances in precision medicine, and translate these to improve healthcare.
The PMHC joins together faculty with a common purpose and connects faculty with expertise in precision medicine to address health problems using an interdisciplinary approach. It is our belief that a interdisciplinary group will more quickly advance research, educational, and outreach activities.
Members of the PMHC also bridge the gap between genetic research discoveries and application in patient care. Precision Medicine is a national priority and this group strives to keep on the forefront of this evolving field.
Wylie Burke, M.D., Ph.D.
Wednesday, April 12, 2017
"Working Together on Pharmacogenetics: Report on a Tribal-University Partnership"
Fairview Health Services is working with a local genetics research firm to determine if DNA tests can steer patients to more effective treatment for high blood pressure.
A new project titled "U-PGx" aims to make effective treatment optimization accessible to every European citizen. The U-PGx consortium will examine whether pre-emptive genotyping of an entire panel of genetic markers is cost-effective and results in a better outcome for patients.
A new resource is available on PharmGKB to help researchers and clinicians more easily and quickly understand CPIC recommendations and how to find supporting information on the PharmGKB website.
The ASCO Post highlighted the extraordinary response to targeted therapy of a patient with an adult medulloblastoma brain tumor, the first such report in the first-line setting using hedgehog inhibitor vismodegib (Erivedge). The case report was published in
"Minnesota Precision Medicine Collaborative: Transforming health and advancing equity," was named one of eight U of M Grand Challenges Research collaboration grants to advance the research goals of the TC Campus Strategic Plan over the next ten years.
Development of a clinical precision medicine program in ovarian cancer as a paradigm for 21st century tailored health care solutions
In a recent survey designed to measure public attitudes about the Precision Medicine Initiative (PMI) Cohort Program, a majority of respondents expressed willingness to participate in the nationwide research effort.